Cover Image

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme

The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fi...

Full description

Saved in:
Bibliographic Details
Main Authors: Valenzuela, Claudia (Author) , Torrisi, Sebastiano Emanuele (Author) , Kahn, Nicolas (Author) , Quaresma, Manuel (Author) , Stowasser, Susanne (Author) , Kreuter, Michael (Author)
Format: Article (Journal)
Language:English
Published: [2020]
In: Respiratory research
Year: 2020, Volume: 21
ISSN:1465-993X
DOI:10.1186/s12931-019-1269-6
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-019-1269-6
Get full text
Author Notes:Claudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, Manuel Quaresma, Susanne Stowasser, Michael Kreuter
Description
Summary:The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fibrosing interstitial lung diseases.
Item Description:Gesehen am 30.03.2020
Physical Description:Online Resource
ISSN:1465-993X
DOI:10.1186/s12931-019-1269-6

Similar Items